Dont hold your breath guys, yes you may get a Spec trade spike, but the reality is Oraline IV missed the boat 8 years ago. Manufacturing, shelf life, IP protections problems, failure to secure FDA, competitors now have FDA, the onset of electronic testing, supplies having to pull Oraline IV from there lines are hardly going to want to restock. I could go on and on. It was a great product 10 years ago when it had the edge on the others, but is long gone. SBN has money in the bank....because it my money from endless CR and their low burn rate is because the company was closed, every one sacked, NJ plant in the USA shut down, it was just a shell company looking for a reason to exist. When HGR first tool over SBN when the product was new and exciting the share price was 0.014 the same as today. Except the product is now a known has been and there are far better and well established suppliers.
SBN will have to pull a rabbit out of the hat one this one.
- Forums
- ASX - By Stock
- SBN
- small cap bio, massive potential only $4m m/c
small cap bio, massive potential only $4m m/c, page-15
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online